JUST ANNOUNCED! Our day 2 Peptide Showcase session is FULL! We are so excited to hear from JP Robles from VIAN Therapeutics, Michael Lipp, Ph.D. from Decoy Therapeutics Inc., Rick Ewing from Rapafusyn Pharmaceuticals, Hans Melo from Menten AI, and Fa Liu from Full-Life Technologies! Register today at: https://lnkd.in/gtcdZW6a Thank you to our SAB members who helped make this session possible! Wendy Hartsock from Aralez Bio, Christopher McGee, Ph.D. from Bachem. #peptide #peptides #peptidechemistry
关于我们
Rapafusyn Pharmaceuticals is an emerging pharmaceutical development company located in Baltimore Maryland. Rapafusyn has licensed technology related to a novel class of natural product-like macrocycles from Johns Hopkins University School of Medicine and seeks to develop novel pharmaceuticals to treat patients having diseases and fulfill unmet medical needs.
- 网站
-
https://www.rapafusyn.com
Rapafusyn Pharmaceuticals的外部链接
- 所属行业
- 研究服务
- 规模
- 11-50 人
- 总部
- Baltimore，Maryland
- 类型
- 私人持股
- 创立
- 2015
- 领域
- Pharmaceutical Research and Development、Chemistry、Research和Macrocycles
地点
Rapafusyn Pharmaceuticals员工
-
Sean X. Hu
CEO of Rapafusyn Pharmaceuticals, where we break the pharma industry's drug-discovery-bottleneck using our macrocyclic "molecular glue" platform
-
Rick Ewing
VP, Head of Chemistry, Rapafusyn Research and Development
-
宋豪麟
鑽石生技投資總監
-
Matt Gross
Vice President of Business Development at Rapafusyn Pharmaceuticals
动态
-
Rapafusyn Pharmaceuticals Closes $28 Million Series A Financing - https://lnkd.in/gGgHyagV Follow #citybiz on LinkedIn - https://lnkd.in/eBgXKiz8 Rapafusyn Pharmaceuticals, 3E Bioventures, Proxima Ventures, Sean X. Hu, Karen Liu, Haolin Sung, #researchsearvices #pharmaceuticals #seriesafunding #venturecapital #capitalinvestment #drugs #therapeutic
-
Rapafusyn is excited to announce the initial closings of our A financing round with high-quality investors including 3E Bioventures, Proxima Ventures, and Lapam Capital. Together, we look forward to advancing our non-degrading molecular glue platform and accelerating our effort to discover and develop transformational drug therapeutics for the high unmet medical needs of patients. https://lnkd.in/etJV9Tjk
Rapafusyn Pharmaceuticals Secures $28 Million Series A to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform — RAPAFUSYN
rapafusyn.com
-
Rapafusyn is excited to announce the initial closings of our A financing round with high-quality investors including 3E Bioventures, Proxima Ventures, and Lapam Capital. Together, we look forward to advancing our non-degrading molecular glue platform and accelerating our effort to discover and develop transformational drug therapeutics for the high unmet medical needs of patients. https://lnkd.in/etJV9Tjk
Rapafusyn Pharmaceuticals Secures $28 Million Series A to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform — RAPAFUSYN
rapafusyn.com
-
Rapafusyn is pleased to announce two presentations at the Drug Discovery Chemistry Meeting, April 1 – 4 in San Diego.?Dr. Rick Ewing, VP of Medicinal Chemistry, will be giving an oral presentation on Rapafusyn’s Non-Degradation Molecular Glue platform and Dr. Sam Hong will be presenting a poster on our industry leading libraries of molecular glues. Go to https://lnkd.in/dNkqe6qQ for more details.
-
-
Rapafusyn Pharmaceuticals is proud to announce Dr. Rick Ewing, Vice President of Medicinal Chemistry, has been recognized for his outstanding accomplishments with two distinguished awards.?Rick has received both the 2023 American Chemical Society (ACS) Philadelphia Section Award, and the 2023 Edison Patent Award in Biotechnology – congratulations Rick!?For more information go to https://lnkd.in/eGr94knP
Rapafusyn's Dr. Rick Ewing Acknowledged with Dual Honors for Exceptional Achievements — RAPAFUSYN
rapafusyn.com
-
Join us as we share innovative insights, groundbreaking solutions, and a vision for the future!
Rapafusyn Pharmaceuticals Presents At The Second Annual Molecular Glue Summit In Boston, MA On January 31 - February 1 | BioSpace
biospace.com
-
Rapafusyn is thrilled to announce two presentations at the upcoming Molecular Glue Drug Discovery Summit, Jan 31 – Feb 1 in Boston.?Dr. Rick Ewing, VP of Medicinal Chemistry, will be giving an oral presentation on Rapafusyn’s Non-Degradation Molecular Glue platform and Dr. Matthew Olson will be presenting a poster on our ENT1 program for the treatment of Acute Kidney Injury. Go to https://lnkd.in/dNkqe6qQ for more details.
-